原發(fā)性肝癌是中國(guó)癌癥第2大死因，其中肝細(xì)胞癌占80%～90%，各種治療方法療效欠佳，總體生存期較短。以免疫檢查點(diǎn)抑制劑為核心的免疫治療在肝細(xì)胞癌臨床研究中表現(xiàn)出較好療效，并獲得相關(guān)指南支持。對(duì)于晚期肝細(xì)胞癌，免疫檢查點(diǎn)抑制劑可單藥或雙藥聯(lián)用，可聯(lián)合血管內(nèi)皮生長(zhǎng)因子抑制劑或酪氨酸激酶抑制劑。對(duì)早期和中期肝癌，免疫檢查點(diǎn)抑制劑可聯(lián)合局部治療。此外，免疫細(xì)胞治療也逐漸進(jìn)入臨床試驗(yàn)階段。就肝細(xì)胞癌免疫治療臨床研究的最新進(jìn)展進(jìn)行綜述，以期為臨床應(yīng)用和深入研究提供參考。

Primary liver cancer is the second leading cause of cancer death in China, of which hepatocellular carcinoma (HCC) accounts for 80%-90%. The therapeutic response of HCC is limited, with relatively disappointing overall survival. Immunotherapies, especially immune checkpoint inhibitors (ICI) have shown promising results in the systematic treatment of advanced or unresectable HCC with support by several guidelines. For advanced HCC, ICI can be used alone or in combination with another ICI, vascular endothelial growth factor inhibitors or tyrosine kinase inhibitors. For early- and middle-staged HCC, ICI could work with local-regional treatment. In addition, clinical trials evaluating the efficacy and safety of immune cell therapy are conducted. In this review, we summarized the latest progress of immunotherapy for HCC in order to provide some references for clinical application and further research.

R979.1

國(guó)家自然科學(xué)基金資助項(xiàng)目（82104651）；國(guó)家重點(diǎn)研發(fā)計(jì)劃資助項(xiàng)目（2018YFC1705102）